Smoking cessation is the most important strategy available to reduce lung cancer risk. To date, there has been no research on tobacco cessation in lung screening patients, who may have unique attributes (e.g., anxiety about having a nodule coupled with tobacco dependence). We thus propose to evaluate 2 novel behavioral interventions as adjuncts to standard pharmacotherapy. We will enroll and randomize 276 patients undergoing lung screening to Intervention 1 (gain-framed personalized video and print intervention). We will evaluate whether this will improve tobacco quit rates above and beyond standard of care smoking cessation treatment over 8 weeks. Then we will perform a second randomization to Intervention 2, an individual-level, biofeedback intervention. We will then evaluate whether this intervention will reduce smoking rates at 6 months.
This research is a randomized smoking cessation trial conducted within and specifically personalized for lung cancer screening patients presenting to a lung screening clinic. Novel tobacco treatments for this population are critically needed, given the growing population of lung screening patients. In the proposed study, we will test a gain-framed messaging intervention specifically designed for lung screening patients (vs. unframed messaging), as well as evaluating NRT sampling (vs. no medication).